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ABSTRACT
LOPEZ, P., D. R. TAAFFE, R. U. NEWTON, and D. A. GALVÃO. Resistance Exercise Dosage in Men with Prostate Cancer: Systematic
Review, Meta-analysis, and Meta-regression.Med. Sci. Sports Exerc., Vol. 53, No. 3, pp. 459–469, 2021. Purpose: Resistance exercise im-
proves an array of treatment-related adverse effects in men with prostate cancer; however, the minimal dosage required is unknown. We system-
atically reviewed the resistance training effects in prostate cancer patients to determine the minimal dosage regarding the exercise components
(type, duration, volume, and intensity) on body composition, physical function, muscle strength, cardiorespiratory fitness, body mass index,
and prostate-specific antigen.Methods:Using PRISMA guidelines, MEDLINE, CINAHL, EMBASE, SPORTDiscus, andWeb of Science da-
tabases were searched. Eligible randomized controlled trials examined prostate cancer patients undertaking resistance-based exercise programs
during or after treatment.Meta-analysis was undertakenwhenmore than three studies were included. Associations betweenmean differences and
exercise components were tested by univariate and multivariate meta-regression analysis.Results: Twenty-three articles describing 21 trials and
involving 1748 prostate cancer patients were included. Exercise improved fat mass (−1% in body fat and −0.6 kg in fat mass), lean mass (~0.5 kg
in lean and appendicular lean mass), functional capacity (i.e., chair rise, 400-m test, 6-m fast walk, and stair climb tests), and fitness outcomes
(i.e., V̇O2peak and muscle strength) (P = 0.040–<0.001) with no change in body mass index or prostate-specific antigen (P = 0.440–0.735).
Meta-regression indicated no association between exercise type, resistance training duration, weekly volume and intensity, and primary outcomes
(P = 0.075–0.965). There was a significant association between exercise intensity and chest press muscle strength (favoring moderate intensity,
P = 0.012), but not in other secondary outcomes.Conclusion: In untrained older men with prostate cancer initiating an exercise program, lower
volume at moderate to high intensity is as effective as higher volume resistance training for enhancing body composition, functional capacity, and
muscle strength in the short term. A low exercise dosage may help reduce barriers to exercise and enhance adherence.KeyWords: PROSTATE
CANCER, RESISTANCE TRAINING, DOSE–RESPONSE EFFECTS, MINIMAL DOSAGE, HEALTH-RELATED OUTCOMES
Thebenefits of exercisemedicine have beenwidely attestedin different cancer populations (1,2). In prostate cancerpatients, for example, resistance exercise alone or com-
binedwith aerobic training has been shown to reduce postsurgical
impairments from prostatectomy (3), reverse the array of adverse
effects from androgen deprivation therapy (ADT) (4–11), and
preserve physical function in those with bone metastases (12),
in addition to improvements in quality of life (5,8,12). However,
although the role of exercise medicine is being expanded to in-
clude low-grade cancer patients undergoing active surveillance
(13–15), or high-grade patients to enhance tumor growth sup-
pression (16) and survival (17), information regarding the actual
exercise dose–response still needs to be determined (18).
Considering the overall exercise benefits in prostate cancer
patients, the assumption that a given exercise dosage will pro-
mote benefits in all outcomes is premature. In the most recent
exercise guideline for cancer patients (19), a specific resistance
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exercise dosage (e.g., 2 sets of 8–15 reps at 60%–85% of
one-repetition maximum [1-RM]) was recommended to ad-
dress or counter anxiety, fatigue, and depressive symptoms
based on high-quality publications. However, the dispropor-
tionately large number of breast cancer trials compared with
other cancer trials from which the recommendations were de-
rived precludes more accurate recommendations for prostate
cancer patients (19). Further, the paucity of comparative trials
regarding resistance training components (i.e., frequency, intensity,
and volume)makes it difficult to establish the dose–response effect
on commonly reported outcomes. In this report, we examined the
resistance exercise dosage in body composition and functional
capacity given their strong association with risk of progression
and mortality in prostate cancer patients (20–23).
Thus, the aim of the present study is 1) to systematically review
and analyze the resistance training effects on body composition
measures, functional capacity tests, cardiorespiratory fitness, mus-
cle strength, bodymass index (BMI), and prostate-specific antigen
(PSA) levels and 2) to verify the minimal dose regarding the
prescribed exercise components (i.e., type, duration, volume,
and intensity) and effects on these outcomes.
METHODS
Study selection procedure. The study was undertaken
in accordance with the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses statement (24,25), and the
method used was based on the minimum criteria established
by the Cochrane Back Review Group (26). This systematic re-
view was not registered in any prospectively systematic re-
view database (e.g., PROSPERO).
This review included published data from randomized con-
trolled trials that evaluated the effects of resistance-based exer-
cise programs in prostate cancer patients at any treatment stage
(e.g., presurgical, during treatment, and with bonemetastases).
The primary outcomes of this review were body composition
(i.e., body fat percentage, fat mass, trunk fat mass, lean mass,
and appendicular lean mass) and functional capacity tests (i.e.,
30-s sit-to-stand test, 6-min walk, 400-m walk, 6-m usual and fast
walk, timed up-and-go, stair climb, and repeated sit-to-standwhere
patients repeated the task 5 times). The secondary outcomes
were cardiorespiratory fitness (i.e., V̇O2peak or V̇O2max), muscle
strength (i.e., chest press, leg press, leg extension, and seated
row), PSA, and BMI. Trials were excluded if 1) home-based ex-
ercisewas used in thewhole intervention period; 2) they involved
mixed cancer patients without specific information on prostate
cancer patient results; 3) they did not include or report the specific
outcomes included in this review, or did not include sufficient in-
formation for analysis; and 4) they were written in a language
other than English. Eligibility was assessed independently eval-
uated in duplicate, with differences resolved by consensus.
The search was conducted up to November 2019 using
the following electronic databases: MEDLINE, CINAHL,
EMBASE, SPORTDiscus, and Web of Science. The terms
used were “prostate cancer” and “resistance training” in asso-
ciation with a list of sensitive terms to search for experimental
studies. In addition, we performed a manual search of the
reference lists provided in the selected articles as well as pre-
vious systematic reviews and meta-analytic studies (27–32)
to detect studies potentially eligible for inclusion. The search
strategy used is shown in Table S1 (see Supplemental Digital
Content 1, Literature search strategy used for the PubMed da-
tabase, http://links.lww.com/MSS/C125).
Data extraction. Titles and abstracts of all articles identi-
fied by the search strategy were independently evaluated in
duplicate. Abstracts that did not provide sufficient information
regarding the inclusion and exclusion criteria were selected for
full-text evaluation. In the second phase, the same reviewers
independently evaluated these full-text articles and selected
them in accordance with the eligibility criteria. Disagreements
between reviewers were resolved by consensus. The data ex-
traction was performed via a standardized form. Information
on the interventions, outcomes, and patients were collected.
Study characteristics, intervention duration, components of the
resistance training prescription (i.e., frequency, intensity, vol-
ume, and type), adherence (i.e., number of patients that
completed the program), attendance (i.e., number of sessions
attended), compliance (i.e., number of patients that successfully
completed the exercise prescription), and adverse events were
extracted, along with the main outcomes. The prescribed resis-
tance training was summarized as follows: frequency (number
of sessions per week), intensity (prescribed intensity of resis-
tance training), type (resistance training, combined resistance
and aerobic training, or multimodal exercise program), and
volume (sets and repetitions). When studies incorporated su-
pervised and unsupervised periods of training, information
was extracted on the longest period of the supervised exercise
intervention. Outcomes were extracted in their absolute units
(e.g., kilograms for lean and fat mass assessments). When
graphs were used instead of numerical data, the graphs were
measured through their plots using a specific tool for data ex-
traction (WebPlotDigitizer, San Francisco, CA) (33).
Assessment of risk of bias. Risk of bias of individual
studies was evaluated according to the second version of the
Cochrane risk of bias tool for randomized trials (RoB 2) (34), fo-
cusing on different aspects of the trial design, conduct, and
reporting. Each assessment using the RoB 2 tool is focused at
the outcome level. The six-item instrument evaluates 1) random-
ization process, 2) deviation from intended interventions, 3)
missing outcome data, 4) measurement of the outcome, 5) selec-
tion of the reported result, and 6) overall bias, and it was used to
evaluate each included randomized controlled trial for each out-
come of interest. Risk of bias for each of the six domains was
expressed as “low risk,” “some concern,” and “high risk” (34).
Data analysis. The pooled-effect estimates were obtained
from the mean difference of baseline to the final assessment of
the intervention for each group. These values were expressed
as the mean difference between groups. In studies with mul-
tiple exercise interventions, the groups were divided with
each respective sample size, within-group mean difference,
and SD or 95% confidence interval (CI) for further analysis.
Meta-analyses were conducted for overall studies, and a
subgroup analysis was provided based on RoB 2.0 low-risk












classification when more than three studies were included.
Calculations were performed using a random-effects model
(35). The level of significance was set at P ≤ 0.05. Statistical
heterogeneity was assessed using the CochranQ test. A threshold
P value of 0.1 as well as values greater than 50% in the statistical
test of heterogeneity (I2) were considered indicative of high
heterogeneity (36). Heterogeneity between studies was explored
by omitting one study at a time and comparing the pooled with
the original estimates, whereas the presence of publication bias
was explored by contour-enhanced funnel plots along with
Egger’s test, considering a P value <0.1 as indicative of publica-
tion bias (37,38). When necessary, the trim-and-fill computation
was used to estimate the effect of publication bias on the interpre-
tation of results (39,40). Analyses were conducted using the
package metan, confunnel, metabias, and metatrim from Stata
14.0 software (Stata, College Station, TX). Forest plots presented
for the outcome measures are after sensitivity analysis and/or
trim-and-fill procedure adjustments.
In addition, we tested the association between the mean
difference effect and the exercise components to identify a
dose–response relationship using univariate and multivariate
meta-regression. Using one variable at a time or multivariable
models, we assessed whether components such as type, inter-
vention duration, prescribed weekly volume, and peak intensity
influence the association of resistance-based exercise with the
main effects. Analyses were undertaken in outcomes signifi-
cantly affected by exercise provided the models had more than
five studies. For intervention duration, prescribed weekly vol-
ume, and peak intensity, analyses were considered when the
values presented a range higher than 5%, whereas exercise type
was coded as 0 = resistance training alone and 1 = resistance
training combinedwith other components (e.g., aerobic, flexibility,
impact loading, or balance). Analyses were conducted using
the package metareg from Stata 14.0 software.
RESULTS
Studies included.All studies selected reported the aim to
investigate the effect of resistance training (i.e., resistance
training alone, combined with aerobic exercise, or included
in a multimodal exercise program) in prostate cancer patients
at any treatment stage. We retrieved 1021 studies, 794 of
which were retained for screening after duplicate removals.
Of these, 694 were excluded and 100 full-text articles were
assessed for eligibility (Fig. 1). The eligibility assessment resulted
in 23 articles (describing 21 trials) (5–12,41–55), which were in-
cluded in the present review and meta-analyses (see Table S2,
Supplemental Digital Content 2, Study characteristics: treatment
stage, sample size, exercise prescription, adherence, attendance,
compliance and outcomes assessed, http://links.lww.com/MSS/
C126), with 6 to 13 studies being included in the dose–
response relationship analysis involving exercise type, interven-
tion duration, prescribed weekly volume, and peak intensity.
Prostate cancer patients and exercise intervention
characteristics. A total of 1748 prostate cancer patients
with an average age of 69.5 ± 2.1 yr participated in the included
studies. Exercise interventions were predominantly undertaken
in patients on ADT (17 of 23 studies) (5,7–9,11,41,43–48,
FIGURE 1—Flow chart of study selection process. *Primary outcome.










51–55). Exercise modality included predominantly com-
bined resistance and aerobic training (12 of 23 studies)
(5–7,9,10,41,43,45,50–52,55) followed bymultimodal exercise
program (4 of 23 studies) (11,12,48,54), resistance training plus
impact loading (5 of 23 studies) (7,9,44,46,49), and resistance
training only (4 of 23 studies) (8,42,47,53) in a cohort of 901
patients allocated to the intervention group compared with
847 patients in the control group. In addition, three studies
(41,43,48) also provided nutrition advice during the intervention.
Studies were designed to compare the exercise intervention
versus usual care control (15 of 23 studies) (5,8,11,12,
41–43,45,47–52,55), a home-based program involving aero-
bic or flexibility training and physical activity (6 of 23 studies)
(6,10,44,46,53,54), or to a delayed exercise group (2 of 23
studies) (7,9). Two studies compared multiple exercise inter-
ventions (7,9).
The mean exercise intervention duration was 19.5 ± 10.7 wk
with an average of 2.4 ± 0.7 sessions per week. The average to-
tal prescribed resistance training volume was 9136 ± 4534 rep-
etitions with a weekly training volume of 468 ± 177 repetitions.
In addition, the mean peak intensity reached throughout the re-
sistance training programwas 79%± 8%of 1-RM ranging from
60% to 85%. Information about resistance training frequency
was not reported by one study (53), whereas four studies did
not report volume (41,43,48,54) or intensity (41,50,54,55), re-
spectively. Exercise program adherence ranged from 74% to
100% (reported in 22 of 23 studies) (5–9,11,12,41–55), whereas
attendance and compliance ranged from 65% to 100% (reported
in 21 of 23 studies) (5–12,41,42,44–46,48–55) and from 85% to
94% (reported in 5 of 23 studies) (41,42,47,49,53), respectively.
Adverse events related to the exercise interventions were iden-
tified in 8 studies (6,8,9,45,47,50,51,54), whereas 14 studies
(5,7,11,12,41–44,46,48,49,52,53,55) reported no adverse events
throughout the intervention period. The adverse events were
mostly related to musculoskeletal pain (e.g., back, shoulder,
and knee), and only one study (53) presented a moderate ad-
verse event with no detail provided.
Risk of bias assessment. For the primary outcomes of
this review, 13.3% of the studies presented some concern for
risk of bias in body composition assessment (2 of 15 studies)
(48,55) and 76.9% in the functional capacity tests (10 of 13
studies) (5,6,9,12,42,45,47,50,51,53). The concerns in body
composition were mainly due to the measurement of the
outcome as two studies (48,55) evaluated body composition
outcomes through the use of bioelectrical impedance. For
functional capacity, the concerns were mainly due to the
measurement of the outcome as studies performed nonblinded
assessments onmeasurement of the outcome (76.9%, 10 of 13
studies) (5,6,9,12,42,45,47,50,51,53), and one study (7.7%, 1
of 13 studies) (50) did not report the concealment of allocation
in the randomization process. For the secondary outcomes,
concerns were observed in cardiorespiratory fitness (some
concerns: 60.0%, 3 of 5 studies) (43,53,54), muscle strength
(84.6%, 11 of 13 studies) (5–8,10,12,42,45,47,50,53), and
BMI (16.7%, 1 of 6 studies) (47). Concerns were not observed
in the PSA assessment. The overall risk of bias assessment is
shown in Table S3 (see Supplemental Digital Content 3, Risk
of bias of included studies, http://links.lww.com/MSS/C127),
and the individual assessment is presented in Figure S1 (see
Supplemental Digital Content 4, Individual risk of bias assess-
ment, http://links.lww.com/MSS/C128).
Exercise effects on body composition. Exercise re-
sulted in significant positive overall effects in percent body
fat (−1.0%, 95% CI = −1.3 to −0.6%), fat mass (−0.6 kg,
95% CI = −0.8 to −0.3 kg), trunk fat mass (−0.3 kg, 95%
CI = −0.6 to −0.2 kg), lean mass (0.5 kg, 95% CI = 0.3 to
0.7 kg), and appendicular lean mass (0.4 kg, 95% CI = 0.2
to 0.6 kg) with heterogeneity ranging from I2 = 0% to 47% af-
ter sensitivity analysis and/or trim-and-fill procedure adjust-
ments (Figs. 2 and 3). The samples ranged from 490 to 917
participants (see Table S4, Supplemental Digital Content 5,
Overall and subgroup analysis effects on body composition,
functional capacity, and the secondary outcomes in prostate
cancer patients, http://links.lww.com/MSS/C129). In sub-
group analysis, the main effects were significantly maintained
in the outcomes (I2 = 0% to 47%; P = <0.001 to 0.025). Out-
liers were identified in the overall analysis for body fat per-
centage (6) and trunk fat mass (52) and subgroup analysis of
appendicular lean mass (7), whereas publication bias and
trim-and-fill procedure suggested that data from three studies
were missing for appendicular lean mass (P = 0.050). These
studies were omitted from the abovementioned overall and
subgroup effects (Figs. 2 and 3). The meta-analysis power to
detect changes in body composition was 1 − β = 1.0.
In the dose–response analysis, the univariate (P = 0.075 to
0.965; see Table S5, Supplemental Digital Content 6, Univar-
iate meta-regression on main outcomes mean difference and
exercise type, resistance training duration, weekly volume
and peak intensity, http://links.lww.com/MSS/C130) and mul-
tivariate meta-regression models (P = 0.203 to 0.785; see Ta-
ble S6, Supplemental Digital Content 7, Multivariate
meta-regression on main outcomes mean difference and exer-
cise type, resistance training duration, weekly volume and
peak intensity, http://links.lww.com/MSS/C131) did not ex-
plain the variation in body composition outcomes.
Exercise effects on functional capacity. There was a
significant positive overall exercise effect for the time to per-
form the 30-s sit-to-stand repetitions (2.8 reps, 95% CI = 1.7
to 4.0 reps), repeated sit-to-stand test (−1.0 s, 95% CI = −1.4
to −0.6 s), 400-m walk (−8.3 s, 95% CI = −12.4 to −4.2 s),
6-m fast walk (−0.1 s, 95% CI = −0.2 to −0.0), and stair climb
(−0.2 s, 95% CI = −0.3 to −0.1 s) with a heterogeneity ranging
from I2 = 0% to 45.2% after sensitivity analysis and/or trim-
and-fill procedure adjustments (Fig. 4). The samples ranged
from 213 to 519 participants (see Table S4, Supplemental Dig-
ital Content 5, Overall and subgroup analysis effects on body
composition, functional capacity, and the secondary outcomes
in prostate cancer patients, http://links.lww.com/MSS/C129).
Subgroup analyses were not undertaken on these outcomes
as well as the overall analyses in the 6-min walk test and
6-m backwards walk test given the small number of studies
included (<3). The study of Galvão et al. (12) was considered












an outlier in the 6-m fast walk time analysis and omitted from
the abovementioned results, whereas publication bias was only
found for the 400-m walk (P = 0.063) with no trimming needed
to be performed (data unchanged). The meta-analysis power to
detect change in the 6-m usual walk and timed up-and-go test
was 1 − β = 0.57 and 0.64, respectively, whereas a 1 − β = 1.0
was found for the remaining functional capacity outcomes.
In the dose–response analysis, the univariate (P = 0.182 to
0.341; see Table S5, Supplemental Digital Content 6, Univariate
meta-regression on main outcomes mean difference and exer-
cise type, resistance training duration, weekly volume and peak
intensity, http://links.lww.com/MSS/C130) and multivariate
meta-regressionmodels (P = 0.358; see Table S6, Supplemental
Digital Content 7, Multivariate meta-regression on main out-
comes mean difference and exercise type, resistance training
duration, weekly volume and peak intensity, http://links.lww.
com/MSS/C131) were not statistically significant in explaining
the variation in 400-m test performance. Analyses of 30-s
FIGURE 2—Mean difference effects of resistance-based exercise compared with control on percentage body fat (A), fat mass (B), and trunk fat mass (C).
Overall and subgroup analyses conducted with a random-effects model. Gray and white circles represent study-specific estimates based on risk of bias as-
sessment (low risk and some concern or high risk of bias, respectively); I2 represents the heterogeneity test; diamonds represent pooled estimates of
random-effect meta-analysis. *Combined resistance and aerobic group. #Resistance training plus impact-loading group.










sit-to-stand, 6-minwalk test, 6-m usual and fast walk, stair climb,
and repeated sit-to-stand tests were not undertaken because of the
small number of studies (≤5) reporting on these components. Per-
forming univariate meta-regression resulted in nonsignificant as-
sociations between exercise type, resistance training duration,
weekly volume, and peak intensity with 30-s sit-to-stand (P =
0.311 for exercise type and resistance training duration), 6-min
fast walk (P = 0.165–0.793), stair climbs (P = 0.523–0.930),
and repeated sit-to-stand tests (P = 0.681–0.868).
Exercise effects on secondary outcomes. There
was a significant increase in chest press (3.9 kg, 95% CI = 2.9
to 4.9 kg), leg press (23.5 kg, 95% CI = 15.2 to 31.7 kg), leg
extension (8.8 kg, 95% CI = 6.9 to 10.7 kg), and seated row
strength (5.2 kg, 95% CI = 3.9 to 6.5 kg) with heterogeneity
ranging from I2 = 0% to 77.4% after sensitivity analysis and/
or trim-and-fill procedure adjustments (Fig. 5). The samples
ranged from 321 to 728 participants (see Table S4, Supplemental
Digital Content 5, Overall and subgroup analysis effects on body
composition, functional capacity, and the secondary outcomes in
prostate cancer patients, http://links.lww.com/MSS/C129). Sub-
group analyses were not undertaken for these outcomes because
of the small number of studies that were considered of low risk
(<3). Outlierswere identified in the overall analysis for chest press
(8), leg extension (12), and seated row test (53). Meta-analysis
power to detect change in muscle strength was 1 − β = 1.0.
Regarding V̇O2peak, there was a positive overall effect of
1.3 mL·kg−1⋅min−1 (95%CI = 0.8 to 1.7 mL·kg−1⋅min−1) after
the publication bias and trim-and-fill procedure, suggesting
that data were missing from two studies (P = 0.078; see Table S4,
Supplemental Digital Content 5, Overall and subgroup analysis
effects on body composition, functional capacity, and the second-
ary outcomes in prostate cancer patients, http://links.lww.com/
MSS/C129, and Fig. 6). Finally, exercise did not result in a sig-
nificant change in BMI or PSA levels (P = 0.440–0.735; see
Table S4, Supplemental Digital Content 5, Overall and sub-
group analysis effects on body composition, functional capac-
ity, and the secondary outcomes in prostate cancer patients,
http://links.lww.com/MSS/C129, and Fig. 6). Meta-analysis
power to detect change in V̇O2peak was 1 − β = 1.0, whereas
power for BMI and PSA was 0.25 and 0.57, respectively.
In the univariate dose–response analysis, resistance training
type and intensity (r2 = 64.0%, P = 0.010, and r2 = 100%,
P < 0.001, respectively; see Table S5, Supplemental Digital
Content 6, Univariate meta-regression on main outcomes mean
difference and exercise type, resistance training duration, weekly
volume and peak intensity, http://links.lww.com/MSS/C130) ex-
plained the variation in chest press muscle strength. In the multi-
variate model, gain in chest press muscle strength (r2 = 100%,
P = 0.012; see Table S6, Supplemental Digital Content 7, Multi-
variate meta-regression on main outcomes mean difference and
exercise type, resistance training duration, weekly volume and
peak intensity, http://links.lww.com/MSS/C131) was greater in
studies prescribing resistance training with moderate intensity
(P = 0.022). Although the resistance training volume was sig-
nificant in the univariate model to explain leg extension and
leg press muscle strength (P = 0.043 and 0.050, respectively;
see Table S5, Supplemental Digital Content 6, Univariate
meta-regression on main outcomes mean difference and exer-
cise type, resistance training duration, weekly volume and
peak intensity, http://links.lww.com/MSS/C130), the results
were not maintained in the multivariatemeta-regressionmodel
(P = 0.147–0.204). Dose–response analyses of V̇O2peak and the
seated row test were not undertaken because of the small number
of studies (≤5) reporting on these components. Performing uni-
variate meta-regression resulted in nonsignificant associations
between exercise type, resistance training duration, weekly
volume, and peak intensity with V̇O2peak (P = 0.598–0.651,
see Table S5, Supplemental Digital Content 6, Univariate
meta-regression on main outcomes mean difference and exer-
cise type, resistance training duration, weekly volume and
peak intensity, http://links.lww.com/MSS/C130), whereas
seated row test variation was explained by exercise type (coef-
ficient ± SE; −14.9 ± 2.9,P = 0.014; favoring resistance training
alone), resistance training weekly volume (0.0 ± 0.1, P = 0.032;
favoring higher weekly volume), but not resistance training du-
ration (P = 0.624; see Table S5, Supplemental Digital Content
6, Univariate meta-regression on main outcomes mean differ-
ence and exercise type, resistance training duration, weekly vol-
ume and peak intensity, http://links.lww.com/MSS/C130).
DISCUSSION
The present review produced four important findings in
prostate cancer patients. First, body composition is enhanced
FIGURE 3—Mean difference effects of resistance-based exercise compared with control on leanmass (A) and appendicular leanmass (B). Overall and sub-
group analyses conducted with a random-effects model. Gray and white circles represent study-specific estimates based on risk of bias assessment (low risk
and some concern or high risk of bias, respectively); I2 represents the heterogeneity test; diamonds represent pooled estimates of random-effect meta-
analysis. *Combined resistance and aerobic group. #Resistance training plus impact-loading group.












by resistance exercise (i.e., increase in whole body and re-
gional lean mass and decrease in fat mass) regardless of type,
duration, weekly volume, and peak intensity. Second, exercise
promotes significant improvements in multiple components of
physical function, in a nonlinear dose–response fashion. Third,
muscle strength and cardiorespiratory fitness are improved with
exercise, with greater effects in chest press strength resulting from
resistance training performed at a moderate intensity. Finally,
FIGURE 4—Mean difference effects of resistance-based exercise compared with control on 30-s sit-to-stand repetitions (A), 5 sit-to-stand test (B), 400-m
walk test (C), 6-m usual walk test (D), 6-m fast walk test (E), timed up-and-go test (F), and stair climb test (G). Overall and subgroup analyses conducted
with a random-effects model. Gray and white circles represent study-specific estimates based on risk of bias assessment (low risk and some concern or high
risk of bias, respectively); I2 represents the heterogeneity test; diamonds represent pooled estimates of random-effect meta-analysis. *Combined resistance
and aerobic group. #Resistance training plus impact-loading group. 30SS, 30-s sit-to-stand test; TUG, timed up-and-go test.










resistance-based exercise does not modify BMI or affect PSA
levels. Therefore, the resistance training prescription combined
with different exercise components is a potent therapy against
an array of treatment-related adverse effects in prostate cancer pa-
tients regardless of theweekly volume prescribedwhenmoderate
to high intensity is achieved.
Obesity has been associated with an increased risk of bio-
chemical recurrence and mortality in prostate cancer patients
in a dose–response fashion (20). In the meta-analysis by Cao
and Ma (20), a 5-kg·m−2 increase in BMI was associated with
a 21% increased risk for biochemical recurrence and a 20%
increased risk for prostate cancer–specific mortality. In our
study, PSA levels did not change in response to exercise in-
volving resistance training, indicating no impact of this exer-
cise mode on disease progression (e.g., albeit not expected to
change as most studies were short in duration with the
majority of patients having local disease). In addition, few
studies reported adverse events, and these were generally mi-
nor in nature. Moreover, the similar magnitude of change ob-
served in lean mass and fat mass (i.e., increase in lean mass
and decrease in fat mass) accounts for the maintenance in BMI
and may result in metabolic health benefits and enhanced sur-
vival (56,57). Furthermore, the lack of relationship between resis-
tance training weekly volume, intensity, and duration indicates
the potential benefit of low-dosage resistance training to improve
overall body composition. Likewise, in a previous report by
Stamatakis et al. (58), a low weekly dosage of resistance training
was associated with an approximately 25% reduced risk of
mortality. Thus, undertaking exercise programs that include
resistance training not only results in benefits for body compo-
sition in men with prostate cancer but also may provide a pro-
tective effect against cancer recurrence and cancer-specific
FIGURE 5—Mean difference effects of resistance-based exercise compared with control on chest press (A), leg press (B), leg extension (C), and seated row
(D). Overall and subgroup analyses conducted with a random-effects model. Gray and white circles represent study-specific estimates based on risk of bias
assessment (low risk and some concern or high risk of bias, respectively); I2 represents the heterogeneity test; diamonds represent pooled estimates of
random-effect meta-analysis. *Combined resistance and aerobic group. #Resistance training plus impact-loading group.
FIGURE 6—Mean difference effects of resistance-based exercise comparedwith control on V̇O2peak (A), BMI (B), and PSA levels (C). Overall and subgroup
analyses conducted with a random-effects model. Gray and white circles represent study-specific estimates based on risk of bias assessment (low risk and
some concern or high risk of bias, respectively); I2 represents the heterogeneity test; diamonds represent pooled estimates of random-effect meta-analysis.












mortality even when performed at a low weekly dosage. These
results are of importance for prostate cancer patients and the pre-
scription of exercise for this patient group as it suggests that even
modest amounts of exercise may result in the accrual of signifi-
cant body composition benefits, and this may also contribute to
increased attendance and compliance to an exercise program.
Considering the World Health Organization report (59), the
concept of healthy aging should be seen as the process of de-
veloping and maintaining functional capacity. Several studies
report the association between muscle strength, cardiorespira-
tory fitness, and functional tests with independence, hospitali-
zation rate, and mortality (60–65). Thus, the observed gains in
muscle strength, cardiorespiratory fitness, and functional ca-
pacity support the translation of exercise medicine effects into
functional independence and autonomy in older prostate
cancer patients. For example, the reduction in time to walk
400 m represents an increase in the safety margin before the
threshold for disability and may help to reduce the risk for
complications such as risk for falls and fractures (66,67) and
mortality (21). Reduced risk of mortality is also associated
with enhanced repeated sit-to-stand and stair climb test perfor-
mance (22,23). In this way, the progression of moderate to
high intensity in resistance training combined with other exercise
components appears to be sufficient to achieve significant im-
provements in functional capacity of patients with prostate cancer
regardless of the number of weekly repetitions. Thus, the present
findings provide an appropriate approach for prostate cancer pa-
tients as it allows a conservative exercise prescription commence-
ment (e.g., less repetitions per exercise at moderate to high loads)
and gradual progression according to comorbidities and the
patient’s treatment-related side effects (68). Furthermore, fol-
lowing the nonsignificant relationship between intervention du-
ration and study outcomes, it is also possible to maintain a
low-dosage resistance training program for longer periods, which
may help patients to keep active during and after treatment.
One of the critical considerations in the design of exercise
trials and of its potential and feasibility in cancer patients is re-
lated to the exercise dose–response (18,19,68). However, to
date, the assessment and the quantification of exercise dosage
as well as the lack of reporting preclude a minimal-dosage pre-
scription for prostate cancer patients. The present review and
analysis provide information that less repetitions per exercise
at moderate to high intensity (i.e., 60%–85% of 1-RM) could
be sufficient to achieve significant benefits for prostate cancer
patients, at least in the short term.We hypothesize that because
of the large window for adaptation in these undeveloped qual-
ities, these men adapt at a similar rate within the volumes and
intensities of the studies analyzed, at least over the relatively
short duration of these interventions. Our results partially
agree with previous studies comparing different resistance
training dosages in older adults (69–71), with similar results
for various dosages after 12 wk of training (69,71) but not for
longer training periods such as 20 wk (70,71). This could be
due to the lower threshold for muscular adaptations in untrained
older participants in the initial stages of training and the need for
a greater stimulus after this initial period. However, the lack of
influence of intervention duration suggests the potential use of
low-volume resistance training during longer periods in prostate
cancer patients, different than that observed in healthy older
adults (70,71). Future studies will be necessary to elucidate if
higher dosage and longer duration accrue greater benefits in pros-
tate cancer patients. Furthermore, considering the meta-analytic
adjustments and heterogeneity, the positive exercise results ob-
served in body composition and multiple components of physi-
cal function are likely to be observed across different treatment
phases (e.g., during ADT or after primary treatment). Given the
lower between-studies heterogeneity in the meta-analysis
(I2 < 30%), the observed results in body fat, muscle mass,
6-min walk, 400-m walk, stair climb, repeated sit-to-stand, and
cardiorespiratory fitness indicate that prostate cancer patients
may experience similar benefits in these outcomes regardless
of the treatment phase. Thus, the low-resistance training dos-
age could be a useful strategy to improve body composition
and muscle function in patients at different treatment stages.
The strength of this review and analysis is that it included a
large number of exercise trials encompassing prostate cancer
patients at different disease stages (21 trials reported in 23 ar-
ticles with 1748 patients included) in a conservative approach
using univariate and multivariate meta-regression models, as
well as sensitivity analysis to explore the common objectively
assessed physical health-related outcomes. However, there are
also some limitations that are worthy of comment. First, although
our findings indicate a minimal dosage for health-related out-
comes based on studies undertaken to date, it should not be
seen as an “optimal” dosage for each of the outcomes investi-
gated. Second, the use of prescribed dosage (not the actual
dosage undertaken) may be considered a limitation in the pres-
ent study. Although the compliance ranges from 65% to 94%
in the included studies (41,42,47,49,53), most did not report
this metric, precluding a determination of how much exercise
was actually undertaken in the attended sessions. We recently
reported on compliance in an exercise trial on men with
prostate cancer who had bone metastases (72) and outlined
the methodology and metrics that can be used in future stud-
ies. Finally, the exercise program duration was considered
short in most of the included studies. Only two articles from
the same trial (44,46) lasted longer than 6 months, and as a
result, it is difficult to infer our results regarding exercise
dosage beyond a period of 24 wk in duration. Future trials
involving longer exercise durations will be necessary to con-
firm these results.
In conclusion, the results indicate that there is no difference
in effect when prescribing low- and high-volume or moderate-
and high-intensity resistance exercise in untrained older men
with prostate cancer on body composition, functional capacity,
and muscle strength outcomes, at least in the short term.
Considering the array of benefits observed in the present
study, a low-resistance training weekly volume could represent
a time-efficient approach during and after active treatment,
resulting in higher adherence, attendance, and compliance while
accruing similar health and function benefits to that of higher vol-
ume exercise. We suggest the examination of resistance training










dose–response in future trials to determinewhether aminimal dose
approach could culminate in substantial cancer-related benefits.
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